Complement Inhibition: Attacking the Overshooting Inflammation @fter Subarachnoid Hemorrhage - A phase II trial on the safety and efficacy of C1esterase inhibitor for the acute management of subarachnoid hemorrhage - CIAO@SAH

Haaglanden Medisch Centrum0 个研究点目标入组 128 人开始时间: 2021年3月10日最近更新: 2021年7月5日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•-Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan or lumbar puncture (in the presence of a negative CT-scan);
•-Age = 18 years on admission;
•-WFNS grade 1-5
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 68

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•-Subarachnoid hemorrhage deemed most likely to ‘peri mesencephalic’ origin after consideration of history, clinical examination and radiological findings (including angiographic imaging);
•-Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging);
•-Participation in another clinical therapeutic study;
•-Patients with a known hereditary complement deficiency (including hereditary angioedema);
•-Patients with a history of sensibility to blood products or C1-inhibitor;
•-Patients with a history of thrombosis;
•-Pregnant woman

发起方